Cargando…
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Res...
Autor principal: | Walsh, Garry M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544267/ https://www.ncbi.nlm.nih.gov/pubmed/23326187 http://dx.doi.org/10.2147/BTT.S30133 |
Ejemplares similares
-
Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016) -
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
por: Sahota, Jagdeep, et al.
Publicado: (2018) -
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017) -
Successful treatment of refractory eosinophilic fasciitis with reslizumab
por: Mortezavi, Mahta, et al.
Publicado: (2020) -
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
por: Pérez de Llano, Luis A, et al.
Publicado: (2022)